comparemela.com

Latest Breaking News On - ஷெஹ்னாஸ் சுலிமான் - Page 1 : comparemela.com

Executive Women In Bio Selects Women Ready to Change the

Executive Women In Bio Selects Women Ready to Change the
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

GSK adds neuro prospects, paying $700M to share R&D of Alector s two lead drugs

GSK adds neuro prospects, paying $700M to share R&D of Alector s two lead drugs
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.

Honoring the 2021 Power 50 at the National Diversity & Leade

CONTENT: Press Release HOUSTON, April 15, 2021 /3BL Media/ - DiversityFirstTM will be hosting the 17th Annual National Diversity and Leadership Conference on April 21-22 and April 28-29, 2021. The conference will be held virtually with this year’s theme being “Be a Changemaker”. The four-day conference will honor a number of diverse talent from different industries. In celebration of diversity and inclusion in the workplace, we want to honor women in the C-Suite (CEO, CFO, COO, Senior Executives, etc) from top companies who endeavor to improve not just their departments and companies, but their communities as well. Now we celebrate their hard work and progressive initiatives that serve to make the gender gap in the C-Suite just that much smaller.

Chutes & Ladders—GSK vaccine exec Reichman splits to take biotech CEO post

(Pixabay)                  Welcome to this week s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word or the bad from your shop to Fraiser Kansteiner, and we will feature it here at the end of each week. Another GSK vaccine exec jumps ship for biotech CEO role GlaxoSmithKline Amir Reichman is stepping down. Reichman is leaving his post as head of global vaccines engineering core technology at GSK to eventually head up operations at BiondVax Pharmaceuticals. Reichman will split duties with BiondVax’s founder and CEO Ron Babecoff until March 2 as he wraps his time at GSK. Reichman joined GSK in 2015 as part of a multibillion-dollar deal that saw GSK trade off its oncology assets for Novartis’ vaccines unit. Reichman held various positions at Novartis in its vaccine supply chain unit before becoming director of GSK’s global vaccines supply chain and then head of global vaccines engineering

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.